<i id='9E4EEA4DB2'><strike id='9E4EEA4DB2'><tt id='9E4EEA4DB2'><pre id='9E4EEA4DB2'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Medicare proposal to cover medical devices draws a mixed reaction 
Stoke drug shows lower activity against childhood epilepsy 
ChatGPT in medicine: STAT answers readers' burning questions 
Shifting the focus from loneliness to social health 
State Dept. review finds Biden bears some blame for Afghanistan failures 
ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers 
New air purifier tech could be key to improving indoor air quality 
Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village 
Medical leaders decry Supreme Court decision on affirmative action 
NIH documents show early flaws of $1.6 billion long Covid program 
Apple is now the first public company to be valued at $3 trillion 
McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources 
Psychedelics group wrestles with new pharma identity 
Public health communication lessons from Covid 
New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum 
